Last week we shared some of our recent work on TerraSynth, a generative synthesis planner that addresses the synthesis bottleneck in small-molecule drug discovery. While generative models are good at proposing molecules with desirable properties, they often propose molecules that are difficult to synthesize in practice, slowing down DMTA cycles. TerraSynth makes synthesis planning a native part of the design loop rather than a problem to solve afterward. Integrating TerraSynth into our EMMI platform has helped us focus on the molecules that are worth making to advance our programs. Thanks to Zack and @mileswhen for their incredible work on this.

Terray has been built at the intersection from the moment it was founded, and we recently expanded our digital and visual footprint to reflect this. Our CEO, Jacob Berlin, PhD and CFO, Eli Berlin went into the philosophy at Terray, what makes us stand apart, and how we are bringing together experimentation and AI to transform the speed, cost, and, most importantly, success rate of small molecule drug discovery. Check out our new video about our approach and how EMMI, our platform for drug discovery and development, enables our teams to innovate. For the full blog check out the link in comments!

Last week we announced a big leap forward for universal potency models with EMMI Predict: TerraBind. TerraBind delivers best-in-class potency prediction while running 26x faster and reducing inference cost by 96% relative to standard industry potency models. A key driver of this performance is our collaboration with @nvidia and the integration of the NVIDIA cuEquivariance library. By centering its computational core on triangle attention and multiplication, TerraBind's architecture is uniquely positioned to fully leverage cuEquivariance's GPU-optimized kernels, providing a 3-4x speedup compared to standard implementations. With EMMI Predict: TerraBind at the center of our Generate-Predict-Select workflow, this combination of proprietary data, purpose-built models, and NVIDIA-accelerated hardware is transforming how we discover and optimize small-molecule therapeutics. We're excited to keep pushing the boundaries of predictive chemistry with partners like NVIDIA as we work to bring better medicines to patients faster. Read our blog terraytx.com/insights/emmi-p… Read our arxiv paper arxiv.org/abs/2602.07735

Today we announced EMMI Predict: TerraBind, our universal potency model that dramatically expands Terray’s ability to move molecules to the clinic faster. Far outpacing publicly available models, TerraBind is a cornerstone of Terray’s end-to-end workflow for small molecule discovery and development. Read our blog: terraytx.com/insights/emmi-p…